|Articles|May 9, 2023
American Clinical Research Services Acquires Clinical Site Services and Patient Advertising Guru
Acquisition of two previously merged companies bolsters ACRS’s patient-centric solutions for clinical development.
Advertisement
American Clinical Research Services (“ACRS”) has announced the acquisition of Clinical Site Services (“CSSi”) and Patient Advertising Guru (“PAG”). The acquisition of the two previously merged companies demonstrates ACRS’s focus on inclusive patient centric solutions for clinical development. Both Chris Trizna (CSSi) and Evan Brett (PAG) remain as co-Presidents, joining the ACRS leadership team.
Clinical Site Services is a provider of customized, full-service site centric patient recruitment solutions. CSSi’s Local Enrollment Specialists are former study coordinators, located across the globe, that support sites to generate referrals from within the site, their community, advocacy groups, and local medical practitioners.
Patient Advertising Guru is a niche provider of advertising, providing creative development, media buying, and referral tracking services. PAG is also the creator of Research Study Rockstar, a social media resource for patient recruitment.
Both CCSi and PAG have experience servicing a range of therapeutic areas, including oncology, CNS, metabolic, and women’s health, across 50+ countries.
Reference
Latticework Capital Management’s American Clinical Research Services Acquires Clinical Site Services and Patient Advertising Guru. (2023, May 9). Business Wire.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5